PKPeter Kienbaum

Peter Kienbaum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter Kienbaum has a total of 356 co-authors. Here are the top co-authors by number of shared publications:

  • Jürgen Peters

    16 shared publications
  • Maximilian Sebastian Schaefer

    Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Massachusetts; Center for Anesthesia Research Excellence (CARE), Beth Israel Deaconess Medical Center, Boston, Massachusetts; Department of Anesthesiology, Medical Faculty and University Hospital Duesseldorf, Duesseldorf, Germany

    16 shared publications
  • Norbert Scherbaum

    7 shared publications
  • Martin C. Michel

    Professor of Pharmacology, Biochemisches Forschungslabor, Abteilung für Nieren- und Hochdruckkrankheiten

    6 shared publications
  • Heinz Jakob

    Department of Cardiothoracic Surgery, West-German Heart Center Essen, Essen, Germany

    5 shared publications
  • Holger Eggebrecht

    Department of Cardiology, West-German Heart Center Essen, University of Duisburg-Essen, Essen, Germany

    5 shared publications

Latest Publications

  • Changes in Intraoperative Rocuronium Dosing after the Introduction of Sugammadex and Association with Postoperative Respiratory Complications: A Retrospective Cohort Study

    by Luca J. Wachtendorf, Lars Kaiser, Elena Ahrens, Theresa Tenge, Sophia Riesemann, Xiaohan Xu, Denys Shay, Dario von Wedel, Béla-Simon Paschold, Guanqing Chen, et al.

    Background: Neuromuscular blocking agents dose-dependently precipitate residual neuromuscular blockade and postoperative respiratory complications. The introduction of sugammadex allowed for reversal of even deep neuromuscular blockade and might have provoked more liberal use of neuromuscular blocking agents. The authors investigated whether the introduction of sugammadex led to higher intraoperative rocuronium doses and whether this impacted postoperative respiratory complications. Methods: A total of 163,402 adult patient cases who underwent general anesthesia and received exclusively rocuronium at an academic medical center between 2010 and 2024 were included. Interrupted time series analysis adjusted for patient and procedural characteristics was applied to assess changes in cumulative intraoperative rocuronium doses (milligrams per kilogram body weight) after sugammadex introduction in September 2016. Rocuronium-associated risks of postoperative respiratory complications (postextubation desaturation less than 90%, 7-day reintubation or emergency noninvasive ventilation) and effect modification by use of sugammadex and qualitative (twitch count) versus quantitative (train-of-four ratio) neuromuscular monitoring were evaluated. Reported odds ratios represent the dose–response association (per 1 mg/kg rocuronium increase) within the respective subgroup of patient cases. Results: After a stable baseline (−0.01 mg/kg per year between January 2010 and August 2016; 95% CI, −0.05 to 0.03 mg/kg; P = 0.58), rocuronium doses increased by 0.05 mg/kg annually after introduction of sugammadex (95% CI, 0.03 to 0.07 mg/kg; P < 0.001) from (mean ± SD) 0.83 ± 0.49 mg/kg in August 2016 to 1.20 ± 0.65 mg/kg in January 2024. A total of 9,101 of 108,317 patient cases (8.4%) experienced postoperative respiratory complications. Rocuronium was dose-dependently associated with higher postoperative respiratory complication risks, which was most pronounced among patient cases receiving neither sugammadex nor neuromuscular monitoring (adjusted odds ratio [OR adj ], 1.99 per 1 mg/kg; 95% CI, 1.82 to 2.18; P < 0.001). This association was attenuated when sugammadex was administered (n = 42,141; median dose, 200 mg; interquartile range, 200 to 300 mg; OR adj , 1.08 per 1 mg/kg; 95% CI, 1.01 to 1.16; P = 0.023; P for interaction < 0.001) and abolished with quantitative (n = 25,564; OR adj , 10.94 per 1 mg/kg; 95% CI, 0.85 to 1.03; P = 0.19; P for interaction < 0.001) but not qualitative neuromuscular monitoring (n = 49,045; OR adj , 1.10 per 1 mg/kg; 95% CI, 1.02 to 1.18; P = 0.017; P for interaction < 0.001). Conclusions: Sugammadex introduction was followed by a 45.1% increase in rocuronium doses. While sugammadex attenuated the risk of postoperative respiratory complications, it was completely abolished only with quantitative neuromuscular monitoring.


  • Impact of desflurane removal from the operating room on carbon dioxide emissions at a tertiary academic medical centre: a retrospective cohort study

    by Eva-Lotte Seibold, Luca J. Wachtendorf, Matthew J. Needham, Ricardo Munoz-Acuna, Simone Redaelli, Aiman Suleiman, Dario von Wedel, Nikolai Ratajczak, Edgar J. Remotti, Béla-Simon Paschold, et al.


  • Preoperative SGLT-2 inhibitor use and risk of adverse postoperative events: a single-centre retrospective observational study

    by Theresa Tenge, Sebastian Roth, Elena Ahrens, Luca J. Wachtendorf, Béla-Simon Paschold, Guanqing Chen, René M'PEmbele, Detlef Kindgen-Milles, Anastasia Katsiampoura, Peter Kienbaum, et al.


  • Open Access

    Specialist Palliative Care Consultations in COVID-19 Patients in the ICU—A Retrospective Analysis of Patient Characteristics and Symptoms at a German University Hospital

    by Theresa Tenge, Sebastian Brimah, Daniel Schlieper, Antje Roesel, Jacqueline Schwartz, Manuela Schallenburger, Stefan Meier, Timo Brandenburger, Detlef Kindgen-Milles, Peter Kienbaum, et al.

    COVID-19 patients who may require invasive therapeutic procedures such as extracorporeal membrane oxygenation (ECMO) have high symptom burden and in-hospital mortality. In addition, awake patients on ECMO are new in the intensive care unit (ICU) setting. Inpatient specialist palliative care (sPC) provides support such as symptom control on a physical, psychosocial and spiritual level. The field of sPC in COVID-19 patients is still new and important to investigate. We aim to analyze sPC of COVID-19 patients in the ICU with regard to patient characteristics and symptoms from a palliative care perspective. We conducted a retrospective analysis (03/2020–04/2021) and identified 51 ICU patients receiving sPC. The statistical analysis included descriptive statistics and comparisons of symptoms. The first sPC contact of patients (mean age 69.5 years, 62.7% male) was around 14 days after COVID-19 confirmation, and 43% were treated with ECMO therapy. The baseline symptom burden was high with a focus on weakness (100%), tiredness (98%), dyspnea (96%) and family burden (92%). The symptom intensity significantly decreased during the time period of sPC and COVID-19 treatment (t(99) = 3.119, p = 0.003, d = 0.437). These results help intensivists and sPC clinicians to identify symptoms and the need for sPC in COVID-19 patients. However, studies with prospective and controlled designs need to follow.


  • Open Access

    Peridural Anesthesia and Cancer-Related Survival after Surgery for Pancreatic Cancer—A Retrospective Cohort Study

    by Andrea Alexander, Nadja Lehwald-Tywuschik, Alexander Rehders, Stefanie Rabenalt, Pablo E. Verde, Claus F. Eisenberger, Nina Picker, Wolfram Trudo Knoefel, Peter Kienbaum

    Background: In patients with prostatic and breast cancer the application of peridural anesthesia (PDA) showed a beneficial effect on prognosis. This was explained by reduced requirements for general anesthetics and perioperative opioids as well as a lower perioperative stress level. The impact of PDA in patients with more aggressive types of cancer has not been completely elucidated. Here, we analyzed the prognostic influence of PDA on overall survival after surgery as primary in patients that underwent radical resection of pancreatic adenocarcinoma. Methods: Records of 98 consecutive patients were reviewed. In 70 of these cases PDA was applied. Patient characteristics such as demographics, TNM stage, and operative data were retrospectively collected from medical records and analyzed. Survival data were analyzed by Cox’s proportional hazard regression model. Results: Overall, no significant prognostic influence of PDA on recurrence or overall survival (p = 0.762, Hazard Ratio [HR] 0.884, 95% confidence interval [CI] 0.398–1.961) was found. However, there was a trend towards a longer overall survival (p = 0.069, HR 0.394, 95% CI 0.144–1.078) associated with PDA in a subgroup of patients with better differentiation of pancreatic adenocarcinoma. Conclusion: The observation of longer survival associated with PDA in our subgroup of patients with better-differentiated pancreatic carcinomas is in line with previous reports on various other less aggressive tumor entities. Our results indicate that PDA might improve the oncological outcome of patients with pancreatic adenocarcinoma.


  • Open Access

    Treatment of spinal anaesthesia-induced hypotension with cafedrine/theodrenaline versus ephedrine during caesarean section

    by Peter Kranke, Götz Geldner, Peter Kienbaum, Hans Jürgen Gerbershagen, Daniel Chappell, Jan Wallenborn, Susanne Huljic, Tilo Koch, Thomas Keller, Stephan Weber, et al.

    BACKGROUND: In Germany, hypotension induced by spinal anaesthesia is commonly treated with a combination of cafedrine hydrochloride (C, 200 mg) and theodrenaline hydrochloride (T, 10 mg) in 2 ml. We compared the effectiveness of C/T with ephedrine. OBJECTIVES: The primary objectives were to assess the speed of onset and the ability to restore blood pressure without an increase in heart rate. Secondary objectives were to evaluate maternal/foetal outcomes and the number of required additional boluses or other additional measures. DESIGN: HYPOTENS was a national, multicentre, prospective, open-label, two-armed, noninterventional study comparing C/T with ephedrine in two prospectively defined cohorts. This study relates to the cohort of patients receiving spinal anaesthesia for caesarean section. SETTING: German hospitals using either C/T or ephedrine in their routine clinical practice. PATIENTS: Women aged at least 18 years receiving spinal anaesthesia for caesarean section. INTERVENTIONS: Bolus administration of C/T or ephedrine at the discretion of the attending anaesthesiologist. MAIN OUTCOME MEASURES: Endpoints within 15 min after initial administration of C/T or ephedrine were area under the curve between the observed SBP and the minimum target SBP; and incidence of newly occurring heart rate of at least 100 beats min−1. RESULTS: Although effective blood pressure stabilisation was achieved with both treatments, this effect was faster and more pronounced with C/T (P < 0.0001). The incidence of tachycardia and changes in heart rate were higher with ephedrine (P < 0.01). Fewer additional boluses (P < 0.01) were required with C/T. Although favourable neonatal outcomes were reported in both groups, base deficit and lactate values were greater with ephedrine (P < 0.01). Physician satisfaction was higher with C/T. CONCLUSIONS: After C/T, tachycardia was not a problem, providing an advantage over ephedrine. Fewer additional boluses were required with C/T, suggesting greater effectiveness. An increased base deficit with ephedrine suggests reduced oxygen supply or increased demands in foetal circulation. TRIALS REGISTRATION: Clinicaltrials.gov: NCT02893241, German Clinical Trials Register: DRKS00010740.


  • Top Cited Papers
    Open Access

    A rapid positive influence of S-ketamine on the anxiety of patients in palliative care: a retrospective pilot study

    by Eduard Falk, Daniel Schlieper, Patrick van Caster, Matthias J. Lutterbeck, Jacqueline Schwartz, Joachim Cordes, Ina Grau, Peter Kienbaum, Martin Neukirchen

    Background: Patients in palliative care need rapid-acting pharmacological options for psychological distress. N-methyl-D-aspartate antagonist ketamine is known to have a fast onset of anti-depressant and anxiolytic action. Its S-enantiomer S-ketamine (or esketamine) is an analgesic used as a routine treatment for refractory pain as an intravenous infusion (0.25 mg/kg over 45 min). This study investigates whether S-ketamine pain therapy has a positive impact on psychological distress caused by anxiety and depression in palliative care. Methods: Patient routine data from a palliative care unit of a tertiary care hospital were used in a retrospective analysis after positive ethics approval. Eight patients, who received analgesic S-ketamine treatment, were compared to a control group matched by gender and age. The main analysis was conducted using three-way mixed MANOVA followed by two-way mixed ANOVA. Target variables were the values for anxiety and depression in the state-trait anxiety-depression inventory STADI. The predictor variables were the time of measurement before (T1) and after (T2) S-ketamine application and group membership. Results: Comparison of the S-ketamine group (n = 8; 4 male, 4 female; average age 52 years) with the control group (n = 8; 3 male, 5 female; average age 55 years) revealed a significant multivariate effect on anxiety and depression F(1, 14) = 4.78; p = 0.046; r = 0.50. The univariate comparisons showed a significant reduction of the anxiety scores from T1 to T2 in the S-ketamine group compared to the control group F(1, 14) = 10.14; p = 0.007; r = 0.65. With regard to depression, there was no significant reduction from T1 to T2 in the group comparison F(1, 14) = 1.60; p = 0.23; r = 0.32. No long-lasting effects on pain were found. Conclusions: Our findings show that psychological distress of patients in palliative care may improve after a single administration of S-ketamine, which mainly alleviates anxiety in those patients. Limitations of this study arise from non-randomization, retrospective analysis and low sample size. Therefore, further prospective and ideally randomized studies are necessary.


  • Electroencephalography-Guided Anesthetic Administration and Postoperative Delirium

    by Peter Kienbaum, Maximilian S. Schaefer

    To the Editor In a well-designed trial,1 EEG-guided anesthetic administration did not decrease the incidence of postoperative delirium. The authors concluded that their findings do not support the use of EEG-guided anesthesia for this indication. Quantification of consciousness is a complicated endeavor because of the complexity of the underlying biology. Application to clinical practice warrants simplification, which is facilitated by limiting measurements of electroencephalographic oscillations to the frontal cortex with subsequent calculation of markers such as the bispectral index, which was introduced 25 years ago. However, simplified indices, such as the bispectral index, are limited in application to the multidimensional biology of the brain, and the relationship between anesthesia-induced unconsciousness and frontal electroencephalographic patterns has been challenged.2 Compared with the bispectral index, other EEG-based techniques might be more sensitive in detecting anesthesia-associated alterations in consciousness and differentiating signatures associated with increased risk for postoperative delirium. Therefore, we would like to raise caution when applying the results of the ENGAGES trial to the use of EEG-guided anesthesia.